Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | TACR2 | P21452 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28861193 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL60610 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL7459531 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL9213508 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL6839659 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL11069335 | 0.98 | ALDH1A1 (0.45) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL11069331 | 0.98 | ALDH1A1 (0.45) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL28336524 | 0.98 | ALDH1A1 (0.45) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL17768658 | 0.98 | ALDH1A1 (0.45) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A | |
| SCHEMBL29212867 | 0.98 | ALDH1A1 (0.45) | ALDH1A1ALOX15PKMSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | disclosed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| US-10610533-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3527079-A1 | METHODS OF TREATING ORAL MUCOSITIS | Galera Labs, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2056675-B1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2018-11-22 | — | — | US | disclosed |
| EP-3287464-A1 | ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS | Abbott Laboratories (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9855279-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| EP-2859916-B1 | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy | GALERA LABS LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0582489-A1 | Ferroelectric liquid crystal compounds with cyclohexenyl cores and compositions containing them | DISPLAYTECH, INCORPORATED (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5271864-A | Ferroelectric liquid crystal compounds with cyclohexenyl cores and compositions containing them | DISPLAYTECH, INC. (US) | 1993-12-21 | — | — | US | disclosed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ALDH1A1 664/4885ALOX15 540/4885PKM 2522/4885 |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ALDH1A1 664/4885ALOX15 540/4885PKM 2522/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | ALDH1A1 664/4885ALOX15 540/4885PKM 2522/4885 |
| US-10610533-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | ALDH1A1 664/4885ALOX15 540/4885PKM 2522/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | ALDH1A1 664/4885ALOX15 540/4885PKM 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.